ArticleThoracic cancer2021
Stereotactic body radiation therapy for an octogenarian with pulmonary carcinosarcoma.
Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Odontogenic carcinosarcoma: a comprehensive review of clinical and therapeutic insights.Frontiers in oral health · 2025Review
- First-Line Anlotinib Combined with Stereotactic Body Radiation Therapy for an Octogenarian with Pulmonary Carcinosarcoma.Cancer management and research · 2022Article
- Stereotactic body radiation therapy for an octogenarian with pulmonary carcinosarcoma.Thoracic cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary carcinosarcoma is a rare lung tumor accounting for <1% of primary lung cancers, characterized by biphasic components with both carcinomatous and sarcomatous mesenchymal features. This report describes a case of pulmonary carcinosarcoma in an octogenarian who was treated with stereotactic body radiation therapy (SBRT) and whose therapeutic response was sustained for 2 years. Along with other treatment modalities, SBRT might be considered for the treatment of medically inoperable localized stage pulmonary carcinosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.